EE9600170A - Kopolümeer-1 täiustused kopolümeeride kompositsioonides - Google Patents

Kopolümeer-1 täiustused kopolümeeride kompositsioonides

Info

Publication number
EE9600170A
EE9600170A EE9600170A EE9600170A EE9600170A EE 9600170 A EE9600170 A EE 9600170A EE 9600170 A EE9600170 A EE 9600170A EE 9600170 A EE9600170 A EE 9600170A EE 9600170 A EE9600170 A EE 9600170A
Authority
EE
Estonia
Prior art keywords
copolymer
compositions
kilodaltons
species
molecular weight
Prior art date
Application number
EE9600170A
Other languages
English (en)
Other versions
EE03423B1 (et
Inventor
Konfino Eliezer
Sela Michael
Teitelbaum Dvora
Arnon Ruth
Original Assignee
Yeda Research And Development Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26939072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE9600170(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Research And Development Co. Ltd. filed Critical Yeda Research And Development Co. Ltd.
Publication of EE9600170A publication Critical patent/EE9600170A/et
Publication of EE03423B1 publication Critical patent/EE03423B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rehabilitation Therapy (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polyamides (AREA)
EE9600170A 1994-05-24 1995-05-23 Kopolümeer-1, selle valmistamismeetod ja seda sisaldavad kompositsioonid EE03423B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24803794A 1994-05-24 1994-05-24
US34424894A 1994-11-23 1994-11-23
PCT/US1995/006551 WO1995031990A1 (en) 1994-05-24 1995-05-23 Copolymer-1 improvements in compositions of copolymers

Publications (2)

Publication Number Publication Date
EE9600170A true EE9600170A (et) 1997-06-16
EE03423B1 EE03423B1 (et) 2001-06-15

Family

ID=26939072

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9600170A EE03423B1 (et) 1994-05-24 1995-05-23 Kopolümeer-1, selle valmistamismeetod ja seda sisaldavad kompositsioonid

Country Status (31)

Country Link
US (11) US5800808A (et)
EP (1) EP0762888B1 (et)
JP (2) JPH10500955A (et)
KR (1) KR100403750B1 (et)
CN (2) CN1174753C (et)
AT (1) ATE212857T1 (et)
AU (1) AU2602195A (et)
BR (2) BR9507758A (et)
CA (1) CA2191088C (et)
CZ (1) CZ292247B6 (et)
DE (2) DE69525340T2 (et)
DK (1) DK0762888T3 (et)
EE (1) EE03423B1 (et)
ES (1) ES2172586T3 (et)
FI (1) FI120236B (et)
GE (1) GEP20002205B (et)
HK (1) HK1008657A1 (et)
HU (1) HU223473B1 (et)
IL (2) IL113812A (et)
LU (1) LU90987I2 (et)
MD (1) MD1443G2 (et)
NL (1) NL300096I2 (et)
NO (1) NO324528B1 (et)
NZ (1) NZ287335A (et)
PL (1) PL181026B1 (et)
PT (1) PT762888E (et)
SI (1) SI0762888T1 (et)
SK (1) SK283699B6 (et)
TJ (1) TJ392B (et)
UA (1) UA62908C2 (et)
WO (1) WO1995031990A1 (et)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858980A (en) * 1990-03-30 1999-01-12 Autoimmune, Inc. Peptide fragments of myelin basic protein
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US7090982B2 (en) 1991-10-22 2006-08-15 The Governors Of The University Of Alberta Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
HUP0100891A2 (hu) * 1998-02-13 2001-06-28 Autoimmune, Inc. A COP-1 és Th2 fokozó citokinek gyógyászati alkalmazása
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
ES2327301T3 (es) 1998-09-25 2009-10-27 Yeda Research And Development Co., Ltd. Polipeptidos relacionados con el copolimero 1 para su uso como marcadores de pesos moleculares y para uso terapeutico.
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
AU6281599A (en) * 1998-10-02 2000-04-26 Yeda Research And Development Co. Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
US7083777B1 (en) 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
JP4328050B2 (ja) * 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
ZA200206457B (en) * 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
DE60120648D1 (de) * 2000-02-18 2006-07-27 Yeda Res & Dev Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2001093828A1 (en) * 2000-06-05 2001-12-13 Teva Pharmaceuticals Industries, Ltd. The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2001093893A2 (en) * 2000-06-07 2001-12-13 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
WO2001097785A2 (en) * 2000-06-20 2001-12-27 Caprion Pharmaceuticals Inc. Basic copolymers for the treatment of prion-related-disease
IL137460A0 (en) * 2000-07-24 2001-07-24 Yeda Res & Dev Identifying antigen clusters for monitoring a global state of an immune system
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
GB2369896A (en) 2000-12-06 2002-06-12 Marconi Comm Ltd Tunable optical filter actuator
KR100442122B1 (ko) * 2001-07-31 2004-07-30 한국전기연구원 영구 자석을 이용한 브러시리스 발전기
NZ533327A (en) 2001-12-04 2006-11-30 Teva Pharma Processes for the measurement of the potency of glatiramer acetate
NZ533356A (en) * 2001-12-06 2006-10-27 Yeda Res & Dev Vaccine and method for treatment of motor neurone diseases
WO2003059387A2 (en) * 2001-12-21 2003-07-24 Ilex Oncology, Inc. Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
ATE548045T1 (de) 2003-01-07 2012-03-15 Yeda Res & Dev Vakzine in augentropfenform enthaltend copolymer 1 für die therapeutische immunisierung
WO2004064717A2 (en) * 2003-01-21 2004-08-05 Yeda Research And Development Co. Ltd. Cop 1 for treatment of inflammatory bowel diseases
WO2004091573A1 (en) * 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
WO2004089407A2 (en) 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
CA2541445A1 (en) * 2003-10-31 2005-05-12 Teva Pharmaceutical Industries Ltd. Nanoparticles for drug delivery
CA2546077C (en) 2003-11-12 2016-07-05 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
PL1701730T3 (pl) 2003-12-09 2014-04-30 Yeda Res & Dev Sposób i szczepionka zawierająca kopolimer 1 do leczenia zaburzeń psychicznych
EP1725099A4 (en) * 2004-02-02 2009-08-19 Mixture Sciences Inc MIXTURES OF PEPTIDES WITH IMMUNOMODULATORY ACTIVITY
NZ549731A (en) * 2004-03-01 2009-11-27 Peptimmune Inc Methods and compositions for treatment of autoimmune diseases
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
US20050260770A1 (en) * 2004-04-01 2005-11-24 Cohen Irun R Antigen array and diagnostic uses thereof
CA2565819A1 (en) 2004-05-07 2005-12-01 Peptimmune, Inc. Methods of treating disease with random copolymers
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
RU2387453C2 (ru) 2004-06-25 2010-04-27 АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК Композиции и способы лечения неврологических нарушений
KR101317131B1 (ko) * 2004-09-09 2013-10-10 테바 파마슈티컬 인더스트리즈 리미티드 정제된 브롬화 수소산을 이용한 폴리펩타이드류의 혼합물의제조방법
HUE028833T2 (en) * 2004-09-09 2017-01-30 Yeda Res & Dev Polypeptide mixtures, compositions containing them, process for their preparation, and applications
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
JP5297653B2 (ja) * 2004-10-29 2013-09-25 サンド・アクチエンゲゼルシヤフト グラチラマーの製造法
CA2588908C (en) * 2004-11-29 2014-09-23 Yeda Research And Development Co. Ltd Induction of neurogenesis and stem cell therapy in combination with copolymer 1
CN101111252A (zh) * 2005-02-02 2008-01-23 泰华制药工业有限公司 一种通过氢解反应生产多肽混合物的方法
ES2420404T3 (es) * 2005-02-17 2013-08-23 Teva Pharmaceutical Industries Ltd. Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
EP1891233A4 (en) * 2005-04-25 2010-03-24 Yeda Res & Dev MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
JP2009536157A (ja) 2006-04-13 2009-10-08 ペプチミューン，インコーポレイテッド エピトープ透過性の指向された拡張を介した指向性配列ポリマー組成物の設計方法および合成方法
EP2013628B1 (en) 2006-04-28 2016-01-06 Momenta Pharmaceuticals, Inc. Methods of evaluating peptide mixtures
KR100831796B1 (ko) * 2006-05-29 2008-05-28 엘지전자 주식회사 타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
EP2046366B1 (en) 2006-06-28 2016-08-31 Yeda Research And Development Company Limited Copolymer-1 for treatment of age-related macular degeneration
EP2046817B1 (en) * 2006-07-05 2009-12-16 Momenta Pharmaceuticals, Inc. Improved process for the preparation of copolymer-1
CA2690402A1 (en) 2007-06-21 2008-12-24 Momenta Pharmaceuticals, Inc. Copolymer assay
US20090029766A1 (en) * 2007-07-26 2009-01-29 Lutnick Howard W Amusement gaming access and authorization point
EP2173766A1 (en) * 2007-07-31 2010-04-14 Natco Pharma Limited Process for the preparation glatiramer acetate (copolymer-1)
EP2586460A1 (en) 2007-10-16 2013-05-01 Peptimmune, Inc. Method for designing and preparing vaccines comprising directed sequence polymer composition via the directed expansion of epitopes
EP2217250A4 (en) 2007-11-09 2011-01-05 California Inst Of Techn IMMUNOREGULATORY COMPOUNDS AND RELATED COMPOSITIONS AND METHODS
CN101877963A (zh) * 2007-11-28 2010-11-03 泰华制药工业有限公司 延缓临床确诊的多发性硬化症发作的方法
RU2010146489A (ru) * 2008-04-16 2012-05-27 Момента Фармасьютикалз, Инк. (Us) Анализ композиций сополимера аминокислот
ES2537022T3 (es) * 2008-08-07 2015-06-01 Sigma-Aldrich Co. Llc Preparación de polilisina y poliornitina de bajo peso molecular con alto rendimiento
CN102112485B (zh) * 2008-08-07 2013-11-27 台湾神隆股份有限公司 乙酸格拉默(glatiramer acetate)的合成
US9617313B2 (en) 2008-12-24 2017-04-11 Synthon Bv Process for purifying a polymer mixture
WO2010115175A1 (en) 2009-04-03 2010-10-07 Momenta Pharmaceticals, Inc. Control of copolymer compositions
US9150609B2 (en) 2009-06-04 2015-10-06 Council Of Scientific & Industrial Research Process for the preparation of copolymer-1 using a polymer supported dialkylamine initiator
PT2275086E (pt) 2009-07-15 2012-05-18 Teva Pharma Formulação de volume reduzido de acetato de glatirâmero e métodos de administração
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
US8691790B2 (en) * 2009-07-27 2014-04-08 James Layne Boucher Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
DE202010018377U1 (de) 2009-08-20 2016-02-25 Yeda Research And Development Co., Ltd. Niedrigfrequente therapie mit glatirameracetat
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
JP5916622B2 (ja) 2010-01-04 2016-05-11 マピ ファーマ リミテッド グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US20130035390A1 (en) 2010-01-13 2013-02-07 Ramot At Tel-Aviv University Ltd. Treatment of multiple sclerosis
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
DK2555753T3 (en) 2010-04-07 2018-11-26 California Inst Of Techn Vesicle for delivering a compound to a mucosal membrane as well as corresponding compositions, methods and systems
CA2797227A1 (en) * 2010-04-27 2011-11-10 Dr. Reddy's Laboratories Ltd. Preparation of polypeptides and salts thereof
WO2011146910A1 (en) 2010-05-20 2011-11-24 Round June L Antigen specific tregs and related compositions, methods and systems
EP2598889A4 (en) * 2010-07-29 2014-01-22 Reddys Lab Ltd Dr MOLECULAR WEIGHT MARKER FOR GLATIRAMERACETATE
KR20140019296A (ko) 2010-10-11 2014-02-14 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응의 예측성 바이오마커로서의 사이토카인 바이오마커
WO2012123959A2 (en) 2011-02-14 2012-09-20 Usv Limited Copolymer-1, process for preparation and analytical methods thereof
ES2601892T3 (es) * 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
US20140348861A1 (en) 2011-05-05 2014-11-27 National Institute Of Immunology Synthetic peptides and random copolymers for the treatment of autoimmune disorders
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
WO2013009864A1 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Structure assessment of heterogeneous polypeptide mixtures
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
EP2765857A4 (en) 2011-10-10 2015-12-09 Teva Pharma SIMPLE NUCLEOTIDE POLYMORPHISMS USEFUL FOR PREDICTING CLINICAL RESPONSE TO GLATIRAMERATE ACETATE
EP2642290A1 (en) 2012-03-19 2013-09-25 Synthon BV Glatiramer acetate human monocytic cell line-based potency assay
WO2013139728A1 (en) 2012-03-19 2013-09-26 Synthon Bv Glatiramer acetate human monocyte cell-based potency assay
US20140045740A1 (en) * 2012-08-13 2014-02-13 Momenta Pharmaceuticals, Inc. Analysis of glatiramer acetate
US9617596B2 (en) 2012-10-10 2017-04-11 Teva Pharmaceutical Industries, Ltd. Biomarkers predictive for clinical response for glatiramer acetate
WO2014060942A2 (en) * 2012-10-20 2014-04-24 Mahesh Kandula Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
WO2014128079A1 (en) 2013-02-19 2014-08-28 Synthon B.V. Glatiramer acetate multidose formulation
PL2774640T3 (pl) 2013-03-08 2015-04-30 Teva Pharma Wielorazowe urządzenie strzykawkowe dla strzykawki
SI2774639T1 (sl) 2013-03-08 2015-05-29 Teva Pharmaceutical Industries, Ltd. Injektorska naprava za brizgo, primerna za večkratno uporabo
CA2903805A1 (en) 2013-03-14 2014-10-02 Mylan Inc. Glatiramer acetate response biomarker mrna potency assay
WO2014173463A1 (en) 2013-04-26 2014-10-30 Synthon Bv Glatiramer acetate human monocytic cell line-based potency assay
JP2016521284A (ja) 2013-05-10 2016-07-21 カリフォルニア インスティチュート オブ テクノロジー 大腸ガンのプロバイオティクスによる防止および処置
CN103265624B (zh) * 2013-05-27 2015-04-22 成都圣诺生物制药有限公司 格拉替雷的制备方法
CN104371012A (zh) * 2013-08-12 2015-02-25 深圳翰宇药业股份有限公司 一种合成醋酸格拉替雷的方法
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CA2928084A1 (en) * 2013-10-24 2015-04-30 Mylan Inc. Human t cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
EP3090064B1 (en) 2013-12-31 2019-11-13 Yeda Research and Development Co. Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
CN114081946A (zh) 2014-03-12 2022-02-25 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
CN104844697B (zh) 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 醋酸格拉替雷的制备方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
WO2016139659A1 (en) 2015-03-01 2016-09-09 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
WO2017031431A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
EP3147667B1 (en) 2015-09-24 2019-06-12 CHEMI S.p.A. Analysis of the molecular weight distribution of complex polypeptide mixtures
EP3170836B1 (en) 2015-11-23 2018-10-24 Chemi SPA Rp-hplc analysis of complex polypeptide mixtures
CN107522774B (zh) * 2016-06-22 2021-07-02 深圳翰宇药业股份有限公司 一种醋酸格拉替雷制备过程中哌啶残留量的实时控制方法
WO2018002930A1 (en) 2016-06-30 2018-01-04 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
MX2019001999A (es) 2016-08-28 2019-08-29 Mapi Pharma Ltd Proceso para la preparacion de microparticulas que contienen acetato de glatiramer.
SI3506921T1 (sl) 2016-08-31 2023-10-30 Mapi Pharma Ltd. Depojski sistemi, ki vsebujejo glatiramer acetat
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
CA3062964A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
AU2018270396A1 (en) 2017-05-15 2020-01-02 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
WO2019175869A1 (en) 2018-03-12 2019-09-19 Yeda Research And Development Co. Ltd Treatment of a heart disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US4444760A (en) 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
JPS6053535A (ja) 1983-09-02 1985-03-27 Nitto Boseki Co Ltd 規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru) 1984-04-28 1985-09-30 Таджикский государственный университет им.В.И.Ленина Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
CA1279822C (en) 1985-06-18 1991-02-05 Robert L. Hunter Biologically-active copolymers
DD257174A3 (de) 1985-12-20 1988-06-08 Ve Forschungszentrum Biotechno Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
SU1469826A1 (ru) 1986-05-30 1995-11-20 Институт Высокомолекулярных Соединений Ан Ссср Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения
US4828706A (en) 1988-03-07 1989-05-09 Spectrum Medical Industries Process for performing a dialysis operation
US4908404A (en) * 1988-08-22 1990-03-13 Biopolymers, Inc. Synthetic amino acid-and/or peptide-containing graft copolymers
DE8900366U1 (de) * 1989-01-13 1989-08-03 Indag Gesellschaft für Industriebedarf mbH, 69214 Eppelheim Folienbeutel
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
SU1690368A1 (ru) 1989-07-20 1995-08-20 Институт Высокомолекулярных Соединений Ан Ссср Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения
DE3930733A1 (de) 1989-09-14 1991-03-28 Roehm Gmbh Verfahren zur herstellung eines komplexierten arzneimittels
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
JP3345816B2 (ja) * 1991-11-12 2002-11-18 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー コラーゲン様ポリペプチド類
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
AU7368798A (en) 1997-05-06 1998-11-27 Quanta Vision Tissue analysis apparatus
JP4328050B2 (ja) * 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
US6936539B2 (en) * 2003-09-24 2005-08-30 Micron Technology, Inc. Antireflective coating for use during the manufacture of a semiconductor device

Also Published As

Publication number Publication date
HUT75672A (en) 1997-05-28
ES2172586T3 (es) 2002-10-01
US6362161B1 (en) 2002-03-26
US6620847B2 (en) 2003-09-16
SI0762888T1 (en) 2002-08-31
UA62908C2 (uk) 2004-01-15
US7199098B2 (en) 2007-04-03
DK0762888T3 (da) 2002-05-27
MD1443F1 (en) 2000-04-30
CN1310673C (zh) 2007-04-18
TJ392B (en) 2004-10-13
HU9603243D0 (en) 1997-01-28
US6939539B2 (en) 2005-09-06
JP3715600B2 (ja) 2005-11-09
SK283699B6 (sk) 2003-12-02
EP0762888A4 (et) 1997-04-16
EP0762888B1 (en) 2002-02-06
US6048898A (en) 2000-04-11
GEP20002205B (en) 2000-08-25
CN1174753C (zh) 2004-11-10
US20050171286A1 (en) 2005-08-04
CN1152874A (zh) 1997-06-25
ATE212857T1 (de) 2002-02-15
US20040106554A1 (en) 2004-06-03
MD1443G2 (ro) 2000-11-30
US20120077754A1 (en) 2012-03-29
US6342476B1 (en) 2002-01-29
US7625861B2 (en) 2009-12-01
EE03423B1 (et) 2001-06-15
US6054430A (en) 2000-04-25
US20070117757A1 (en) 2007-05-24
NO964976L (no) 1997-01-23
AU2602195A (en) 1995-12-18
FI964600A0 (fi) 1996-11-15
NO964976D0 (no) 1996-11-22
FI964600A (fi) 1996-12-05
CA2191088C (en) 2004-09-28
JP2003105000A (ja) 2003-04-09
KR970703154A (ko) 1997-07-03
BR9507758A (pt) 1997-09-23
JPH10500955A (ja) 1998-01-27
PL317331A1 (en) 1997-04-01
IL113812A0 (en) 1995-08-31
NZ287335A (en) 1999-02-25
CA2191088A1 (en) 1995-11-30
NO324528B1 (no) 2007-11-12
HK1008657A1 (en) 1999-05-14
US20030064914A1 (en) 2003-04-03
BRPI9507758B1 (pt) 2021-03-16
DE10299030I1 (de) 2003-01-23
PT762888E (pt) 2002-07-31
NL300096I2 (nl) 2003-02-03
DE69525340T2 (de) 2002-09-19
WO1995031990A1 (en) 1995-11-30
HU223473B1 (hu) 2004-07-28
US5981589A (en) 1999-11-09
LU90987I2 (fr) 2003-02-25
NL300096I1 (nl) 2002-10-01
EP0762888A1 (en) 1997-03-19
CN1626238A (zh) 2005-06-15
SK149396A3 (en) 1997-08-06
KR100403750B1 (ko) 2006-02-13
DE69525340D1 (de) 2002-03-21
IL133890A0 (en) 2001-04-30
US5800808A (en) 1998-09-01
FI120236B (fi) 2009-08-14
IL113812A (en) 2000-06-29
CZ341096A3 (en) 1997-06-11
CZ292247B6 (cs) 2003-08-13
PL181026B1 (pl) 2001-05-31
US8367605B2 (en) 2013-02-05

Similar Documents

Publication Publication Date Title
EE9600170A (et) Kopolümeer-1 täiustused kopolümeeride kompositsioonides
NZ333993A (en) Compositions of EPO having a single covalently bound N-terminal water-soluble polymer
PT855913E (pt) Formulacoes de ferro-dextrano
DE60204820D1 (de) Antistatische Polymerzusammensetzungen
DK0696297T3 (da) Pyridobisimidazolbaseret stiv stavpolymer
DE60033669D1 (de) Transparente polyamidzusammensetzungen
WO1999017711A3 (en) Autophobic hairspray compositions
DE69406766D1 (de) Polyoxymetalate-Gruppen enthaltende Organosiloxan-Zusammensetzungen
JO1999B1 (en) Isotopes of the hormone 'LH-RH' have their uses and the chemical compounds they contain
DE59108093D1 (de) Spermicides Beschichtungsmittel
FR2656321B1 (fr) Compositions comprenant des copolymeres d'ethylene.
HUP9904128A2 (hu) Szappankészítmény
CA2104079A1 (en) Hydrolyzed Zein as Hair Fixative in Hair Compositions
BR9914980A (pt) Composições para tratamento de tecido tendo reduzida abrasão do tecido

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

QB4A Licence registered

Free format text: EXCLUSIVE LICENSE UNTIL TS KSELI

Name of requester: TEVA PHARMACEUTICAL INDUSTRIES LTD.